Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly
Reference:
Braun, J., McHugh, N. J., Singh, A., Wajdula, J. S. and Sato, R., 2007. Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly. Rheumatology, 46 (6), pp. 999-1004.
Related documents:
This repository does not currently have the full-text of this item.You may be able to access a copy if URLs are provided below.
Official URL:
http://dx.doi.org/10.1093/rheumatology/kem069
Abstract
The more convenient etanercept 50 mg QW dose regimen significantly improves function and QOL in patients with AS, similarly to the standard dosing of 25 mg BIW, supporting its use for AS therapy.
Details
| Item Type | Articles |
| Creators | Braun, J., McHugh, N. J., Singh, A., Wajdula, J. S. and Sato, R. |
| DOI | 10.1093/rheumatology/kem069 |
| Departments | Faculty of Science > Pharmacy & Pharmacology Faculty of Humanities & Social Sciences > Health |
| Refereed | Yes |
| Status | Published |
| ID Code | 27954 |
Export
Actions (login required)
| View Item |
